Chemotherapy News and Research

Latest Chemotherapy News and Research

Chemist discover new strategy to process certain drugs

A prolific University of Missouri chemist has discovered a quicker and easier method for pharmaceutical companies to make certain drugs.

9 Mar 2011

Chemotherapy drugs also kill malaria parasite

A group of researchers from EPFL's Global Health Institute (GHI) and Inserm (Institut National de la Sant- et de la Recherche M-dicale, the French government agency for biomedical research) has discovered that a class of chemotherapy drugs originally designed to inhibit key signaling pathways in cancer cells also kills the parasite that causes malaria. The discovery could quickly open up a whole new strategy for combating this deadly disease.

9 Mar 2011

Study finds increase in oral tongue cancer incidence in young US white females

A UNC study released this week in the Journal of Clinical Oncology finds an increasing incidence of squamous cell carcinoma of the oral tongue in young white females in the United States over the last three decades.

9 Mar 2011

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Plexxikon today announced that it has treated the first patient in a Phase 2 clinical trial in Hodgkin lymphoma with PLX3397. This novel agent is an oral, selective inhibitor that down-modulates two key cell types that are thought to mediate the progression of Hodgkin lymphoma tumors — macrophages and mast cells.

8 Mar 2011

$100 million in grants for medical research announced

More than $100 million in grants was announced this Tuesday for an ambitious research project that will try to find what makes cancer so hard to beat. This project received $21.3 million from the National Health and Medical Research Council grants.

8 Mar 2011

New insight into malaria

A group of researchers from EPFL's Global Health Institute and Inserm has discovered that a class of chemotherapy drugs originally designed to inhibit key signaling pathways in cancer cells also kills the parasite that causes malaria.

8 Mar 2011

New review shows difficulty in delivering high-quality cancer care

A shortage of oncologists and rising costs of chemotherapy and radiation therapies and imaging tests, are making delivering quality cancer care increasingly difficult, according to a new review by researchers at RTI International and Eli Lilly and Company.

8 Mar 2011

UCSF's new pharmacy to focus on direct patient care

Although it won't be obvious to UCSF Medical Center patients, behind the scenes a family of giant robots now counts and processes their medications. With a new automated hospital pharmacy, believed to be the nation's most comprehensive, UCSF is using robotic technology and electronics to prepare and track medications with the goal of improving patient safety.

8 Mar 2011

New discovery can provide insight into lung cancer

A discovery at University of Colorado Cancer Center shows testing lung cancer on a molecular level can produce new insights into this deadly disease.

8 Mar 2011

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics.

7 Mar 2011

BioAlliance Pharma awarded €2 million in funding to study Lauriad mucoadhesive technology

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, today announced the award of €2 million in funding over 30 months from the « Fond Unique Interministériel » (a French program supporting collaborative research projects) including an amount of €743,000 specifically allocated to BioAlliance Pharma.

5 Mar 2011

Medifocus to present on Microfocus APA-1000 at Annual National Interdisciplinary Breast Center Conference

Medifocus Inc. is pleased to announce that two clinical presentations of the Company's breast cancer treatment system, the Microfocus APA-1000, will be made at the 21st Annual National Interdisciplinary Breast Center Conference , March 12-16, 2011 in Las Vegas , NV.

5 Mar 2011

BNCT treatment proves effective in treating recurrent head, neck cancer

Biologically targeted BNCT treatment is based on producing radiation inside a tumour using boron-10 and thermal neutrons. Boron-10 is introduced into cancer cells with the help of a special carrier substance (phenylalanine), after which the tumour is irradiated with lowenergy neutrons.

5 Mar 2011

New research into drugs to prevent brain tumours in children wins vital funding

New research into drugs which could prevent the return of persistent brain tumours in children has won vital funding from two major brain tumour charities.

5 Mar 2011

BCAN to host new forum on March 12 to raise awareness about bladder cancer

Bladder cancer is the fifth most commonly diagnosed cancer, and there are more than 600,000 survivors in the United States, yet most people know nothing about it.

4 Mar 2011

$Chemotherapy, endocrine therapy may increase risk of bone fractures in breast cancer survivors$

Chemotherapy, endocrine therapy may increase risk of bone fractures in breast cancer survivors

The combined effects of chemotherapy and endocrine therapy may increase the risk of bone fractures in breast cancer survivors.

4 Mar 2011

U.S. Representatives, Gene Green introduce bipartisan bill to ensure Medicare reimbursement

U.S. Representatives Ed Whitfield and Gene Green today introduced H.R. 905.

4 Mar 2011

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).

4 Mar 2011

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926 compared to placebo in patients with metastatic or locally advanced, inoperable chondrosarcoma. The trial is expected to enroll over 100 patients worldwide.

3 Mar 2011